Login to Your Account

Ferring Moves CIC Candidate Elobixibat into Phase III Trials

By Marie Powers
Staff Writer

Wednesday, May 8, 2013
Less than a year after licensing constipation drug elobixibat from Swedish biotech Albireo AB, Ferring Pharmaceuticals SA initiated enrollment in two Phase III trials of the investigational compound in chronic idiopathic constipation (CIC).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription